<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">39393315</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>11</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1873-5126</ISSN><JournalIssue CitedMedium="Internet"><Volume>129</Volume><PubDate><Year>2024</Year><Month>Oct</Month><Day>05</Day></PubDate></JournalIssue><Title>Parkinsonism &amp; related disorders</Title><ISOAbbreviation>Parkinsonism Relat Disord</ISOAbbreviation></Journal><ArticleTitle>Changes in fatigue of Parkinson's disease during the recurrent COVID-19 pandemic: Findings from the longitudinal analysis of the PHASE study.</ArticleTitle><Pagination><StartPage>107161</StartPage><MedlinePgn>107161</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.parkreldis.2024.107161</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1353-8020(24)01173-8</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">According to Japanese law, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection during the COVID-19 pandemic falls under Category 2, implying that it necessitates hospitalization, isolation, and significant government participation. The category of infection was lowered to Category 5 in May 2023, meaning that individuals were going back to live their lives as they did before the COVID-19 pandemic. This study aimed to explore changes in the prevalence of non-motor symptoms over a longer four-year period, spanning before and after the COVID-19 pandemic.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We conducted a questionnaire survey between January and February in the following years: 2021, 2022, 2023, and 2024.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The Parkinson's fatigue scale score in 2021 (mean: 35.3) increased significantly in 2022 (49.84), 2023 (49.33), and 2024 (54.71) (p &lt; 0.001). After adjusting for baseline score using a mixed linear model with random intercept, the Parkinson's fatigue scale was significantly increased by 15.9 points (95 % CI: 10.9 to 20.9) in 2022, 13.1 points (7.9-18.3) in 2023, and 16.9 points (11.3-22.6) in 2024 independently of all potential confounders including other non-motor symptoms.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The four years of longitudinal observation during the recurrent COVID-19 pandemic revealed that patients with PD experienced an increase in fatigue. Now, post-COVID-19 fatigue is attracting attention; however, the severity of fatigue may have already deteriorated during the period of recurrent COVID-19 pandemic.</AbstractText><CopyrightInformation>Copyright © 2024 Elsevier Ltd. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kataoka</LastName><ForeName>Hiroshi</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Neurology, Nara Medical University, Nara, Japan. Electronic address: hk55@naramed-u.ac.jp.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Saeki</LastName><ForeName>Keigo</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Epidemiology, Nara Medical University, Nara, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tai</LastName><ForeName>Yoshiaki</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Epidemiology, Nara Medical University, Nara, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nanaura</LastName><ForeName>Hitoki</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Neurology, Nara Medical University, Nara, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kiriyama</LastName><ForeName>Takao</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Neurology, Nara Medical University, Nara, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sugie</LastName><ForeName>Kazuma</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Neurology, Nara Medical University, Nara, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Obayashi</LastName><ForeName>Kenji</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Epidemiology, Nara Medical University, Nara, Japan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>05</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Parkinsonism Relat Disord</MedlineTA><NlmUniqueID>9513583</NlmUniqueID><ISSNLinking>1353-8020</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID</Keyword><Keyword MajorTopicYN="N">Coronavirus</Keyword><Keyword MajorTopicYN="N">Fatigue</Keyword><Keyword MajorTopicYN="N">Non-motor symptom</Keyword><Keyword MajorTopicYN="N">Parkinson's disease</Keyword></KeywordList><CoiStatement>Declaration of competing interest Professor Saeki received research grant from YKK AP Inc.; Ushio Inc.; Tokyo Electric Power Company; EnviroLife Research Institute Co., Ltd.; Sekisui Chemical Co., Ltd.; LIXIL Corp.; KYOCERA Corp.; ENDO Lighting Corp.; and KANEKA corp.; Nihon Chuo Juhan Co., Ltd.; and Daiwa House Industry Co., Ltd. Drs. Obayashi received research grant from YKK AP, Inc.; Ushio, Inc.; Tokyo Electric Power Company; EnviroLife Research Institute Co., Ltd.; Sekisui Chemical Co., Ltd; LIXIL Corp.; Kyocera Corp.; ENDO Lighting Corp.; and Kaneka Corp. Drs. Tai received research grant from Nihon Chuo Juhan Co. The other authors reported no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>8</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>9</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>10</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>12</Day><Hour>13</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>12</Day><Hour>13</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>11</Day><Hour>18</Hour><Minute>7</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39393315</ArticleId><ArticleId IdType="doi">10.1016/j.parkreldis.2024.107161</ArticleId><ArticleId IdType="pii">S1353-8020(24)01173-8</ArticleId></ArticleIdList></PubmedData></PubmedArticle>